Fate Therapeutics price target lowered to $11 from $13 at Canaccord

Canaccord analyst Bill Maughan lowered the firm’s price target on Fate Therapeutics to $11 from $13 and keeps a Buy rating on the shares. The firm said its conference call duscussed both the oncology pipeline and the autoimmune, which appears to have graduated over the past several months from “attractive opportunity” to “thesis driver.”